Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose **oral combination** of three active ingredients: **ibuprofen** (a nonsteroidal anti-inflammatory drug or NSAID), **phenylephrine** (a sympathomimetic decongestant), and **chlorpheniramine** (a first-generation antihistamine). It is used for the short-term relief of symptoms associated with allergies and the common cold, such as runny or stuffy nose, itchy or watery eyes, sneezing, minor aches and pains, headache, sinus pressure, and fever. Ibuprofen blocks cyclooxygenase-mediated prostaglandin synthesis to reduce pain, inflammation, and fever; phenylephrine acts as an alpha-1 adrenergic receptor agonist to vasoconstrict nasal passages; chlorpheniramine competitively inhibits histamine H1 receptors to alleviate allergic symptoms[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + phenylephrine + chlorpheniramine.